Literature DB >> 10556272

Remission of inflammatory arthropathy in association with anti-CD20 therapy for non-Hodgkin's lymphoma.

A Protheroe1, J C Edwards, A Simmons, K Maclennan, P Selby.   

Abstract

We describe a case involving a 53-yr-old male with a marginal zone B-cell lymphoma, associated with an IgM paraprotein and a rheumatoid factor-negative inflammatory polyarthropathy, treated with monoclonal anti-CD20 antibody. During the subsequent 12 weeks, evidence of synovitis reduced to a negligible level, despite no significant change in lymphoma bulk or paraprotein level. The relationship between the lymphoma and the arthropathy, and the likely mechanism of remission of the arthropathy, are discussed in the context of the potential value of anti-CD20 therapy in rheumatoid arthritis.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10556272     DOI: 10.1093/rheumatology/38.11.1150

Source DB:  PubMed          Journal:  Rheumatology (Oxford)        ISSN: 1462-0324            Impact factor:   7.580


  12 in total

1.  B cells in autoimmunity.

Authors:  N A Mitchison; L R Wedderburn
Journal:  Proc Natl Acad Sci U S A       Date:  2000-08-01       Impact factor: 11.205

Review 2.  B cell therapy for rheumatoid arthritis: the rituximab (anti-CD20) experience.

Authors:  T Shaw; J Quan; M C Totoritis
Journal:  Ann Rheum Dis       Date:  2003-11       Impact factor: 19.103

Review 3.  Should rituximab be used to treat antineutrophil cytoplasmic antibody associated vasculitis?

Authors:  O Flossmann; R B Jones; D R W Jayne; R A Luqmani
Journal:  Ann Rheum Dis       Date:  2006-07       Impact factor: 19.103

Review 4.  The long-term impact of rituximab for childhood immune thrombocytopenia.

Authors:  Nichola Cooper; James B Bussel
Journal:  Curr Rheumatol Rep       Date:  2010-04       Impact factor: 4.592

Review 5.  Biologic therapies for juvenile arthritis.

Authors:  N Wilkinson; G Jackson; J Gardner-Medwin
Journal:  Arch Dis Child       Date:  2003-03       Impact factor: 3.791

Review 6.  Drug repurposing: progress, challenges and recommendations.

Authors:  Sudeep Pushpakom; Francesco Iorio; Patrick A Eyers; K Jane Escott; Shirley Hopper; Andrew Wells; Andrew Doig; Tim Guilliams; Joanna Latimer; Christine McNamee; Alan Norris; Philippe Sanseau; David Cavalla; Munir Pirmohamed
Journal:  Nat Rev Drug Discov       Date:  2018-10-12       Impact factor: 84.694

7.  Enumeration and phenotypical analysis of distinct dendritic cell subsets in psoriatic arthritis and rheumatoid arthritis.

Authors:  Sarah L Jongbloed; M Cristina Lebre; Alasdair R Fraser; J Alastair Gracie; Roger D Sturrock; Paul P Tak; Iain B McInnes
Journal:  Arthritis Res Ther       Date:  2006       Impact factor: 5.156

8.  Refractory Sweet's syndrome successfully treated with rituximab.

Authors:  Lucia Seminario-Vidal; Cesar Guerrero; Naveed Sami
Journal:  JAAD Case Rep       Date:  2015-05-02

9.  Erythema Migrans: Course and Outcome in Patients Treated With Rituximab.

Authors:  Vera Maraspin; Petra Bogovič; Tereza Rojko; Eva Ružić-Sabljić; Franc Strle
Journal:  Open Forum Infect Dis       Date:  2019-06-19       Impact factor: 3.835

10.  Targeted Therapy with Rituximab in Felty's Syndrome: A Case Report.

Authors:  Line Heylen; Daan Dierickx; Peter Vandenberghe; René Westhovens
Journal:  Open Rheumatol J       Date:  2012-11-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.